Bocidelpar

DB16906InvestigationalSmall molecule

Bocidelpar: Overview.

Mechanism: Pharmacologically active on Peroxisome proliferator-activated receptor delta
Curator reviewed
Formula / weight: C₂₅H₂₇F₃N₂O₃ · 460.497 g/mol (avg)
Also known as: Hexanoic acid, 3-methyl-6-(2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1h-imidazol-1-yl)methyl)phenoxy)-, (3r)-
Code names: ASP-0367 · MA-0211 · MTB-1

Resolves to

Compound

Structure

InChIKeyFMOPHFSPINWSOV-QGZVFWFLSA-NSMILESC[C@H](CCCOC1=CC=CC=C1CN1C(C)=CN=C1C1=CC=C(C=C1)C(F)(F)F)CC(O)=O

Targets

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bocidelpar, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.